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AbstrAct
Introduction Osteoarthritis (OA) pain is a major 
cause of long-term disability and chronic pain in the 
adult population. One in five patients does not receive 
satisfactory pain relief, which reflects the complexity of 
chronic pain and the current lack of understanding of 
mechanisms of chronic pain. Recently, duloxetine has 
demonstrated clinically relevant pain relief, but only 
in half of treated patients with OA. Here, the aim is to 
investigate the neural mechanisms of pain relief and 
neural signatures that may predict treatment response 
to duloxetine in chronic knee OA pain.
Methods and analysis This is an ongoing single-centre 
randomised placebo-controlled mechanistic study (2:1 
(placebo) allocation), using a multimodal neuroimaging 
approach, together with psychophysiological 
(quantitative sensory testing), genetics and 
questionnaire assessments. Eighty-one subjects 
with chronic knee OA pain are planned to power for 
between-group comparisons (placebo, duloxetine 
responder and duloxetine non-responder). Participants 
have a baseline assessment and, following 6 weeks of 
duloxetine (30 mg for 2 weeks, then 60 mg for 4 weeks), 
a follow-up evaluation. Brain imaging is performed at 
3T with blood-oxygen-level dependent functional MRI 
at rest and during pin-prick nociceptive stimulation for 
main outcome assessment; arterial spin labelling and 
structural imaging (T1-weighted) for secondary outcome 
assessment. Questionnaires evaluate pain, negative 
affect, quality of sleep and cognition.
Ethics and dissemination The study has been 
approved by the East Midlands, Nottingham and is 
being carried out under the principles of the Declaration 
of Helsinki (64th, 2013) and Good Clinical Practice 
standards. Results will be disseminated in peer-
reviewed journals and at scientific conferences.
trial registration number This trial is registered 
at  ClinicalTrials. gov (NCT02208778). This work was 
supported by Arthritis Research UK  
(Grant 18769).
bAckground And rAtIonAlE
Osteoarthritis (OA) is a major cause of long-
term disability and chronic pain in the adult 
population. Knee and hip OA combined 
ranked 11th in a recent survey of global 
burden of disease, and symptomatic knee 
OA is several folds more common than hip 
OA.1 Current treatment options consist 
of a combination of pharmacological and 
non-pharmacological alternatives.2 Despite 
these options, around 20% of patients do 
not get satisfactory pain relief, even after 
undergoing joint replacement surgery.3 This 
strongly supports the notion that chronic 
osteoarthritis pain has a strong central 
component.4–6
Application of advanced neuroimaging 
tools led to novel understanding of central 
mechanisms underpinning acute and chronic 
pain states.7 Functional imaging in particular 
lends itself to the mechanistic study of anal-
gesic treatment.5 8–10 Neuroimaging may also 
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Protocol
strengths and limitations of the study
 ► This study attempts to shed light on the little 
understood mechanisms of pain relief in chronic 
pain.
 ► By undertaking an innovative and integrative 
approach, which combines multimodal 
neuroimaging, quantitative sensory testing and 
psychometric questionnaire assessments, drug 
effects and predictors of treatment response to 
duloxetine are aimed to be identified.
 ► A crossover design would have ideally been 
employed. However, a parallel design was chosen to 
minimise dropout rates.
group.bmj.com on October 23, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
2 Reckziegel D, et al. BMJ Open 2017;7:e014013. doi:10.1136/bmjopen-2016-014013
Open Access 
prove useful in guiding mechanism-based personalised 
therapy.10–12
To comprehensively describe brain activation states 
across regions and functional properties, the concept 
of so-called brain ‘signatures’ has emerged that can be 
derived from regional and network analysis of blood-ox-
ygen-level dependent (BOLD) functional MRI data at 
rest or during controlled stimulation, or from cerebral 
blood flow maps based on arterial spin labelling (ASL) 
techniques.13 14
Duloxetine, a serotonin and norepinephrine reuptake 
inhibitor, has antidepressant and anxiolytic properties 
and is currently also used to treat chronic pain condi-
tions. However, the precise mechanisms by which this 
drug acts to relieve pain are unclear and only around 
50% of patients with OA have sufficient pain relief 
after duloxetine intake15; currently there is no way to 
predict responders.15 16 In healthy participants, duloxe-
tine was found to attenuate activity in affect processing 
areas (amygdala, thalamus, insula and anterior cingu-
late cortex) while simultaneously increasing functional 
coupling between the amygdala and the anterior insula 
during an emotional face matching task.17 Duloxetine in 
major depression augmented connectivity in the ante-
rior default mode network,18 while reduced connectivity 
within the subgenual cingulate was predictive of clinical 
antidepressant response.18
The aim of this study is to investigate the neural 
mechanisms of pain relief in chronic OA pain following 
treatment with duloxetine and to establish multimodal 
brain signatures to predict treatment response. We will 
use a unique multimodal MRI design to identify key 
mechanisms and predictors of duloxetine-induced pain 
relief in chronic OA pain. This will include brain resting 
state functional connectivity, ASL, nociceptive func-
tional (f)MRI, structural T1-weighted brain MRI, proton 
spectroscopy, quantitative sensory testing (QST) and 
questionnaire assessments.
We hypothesise that responding and non-responding 
patients with OA have different limbic signatures, differ-
ences in negative affect and sensory pain phenotypes. 
Additionally, we hypothesise that duloxetine induces func-
tional brain changes in emotional regulatory networks.
PrIMAry objEctIvEs
The objective of this study is to identify a functional 
change in brain signature indexing the analgesic mech-
anism of duloxetine and to identify brain imaging and 
psychophysical markers that predict the response to 
duloxetine treatment.
MAIn hyPothEsEs
 ► Analgesic response to duloxetine treatment can be 
predicted using a range of baseline brain imaging 
markers and QST.
 ► Analgesic response to duloxetine is mediated by 
modulation of neural networks underpinning 
emotional control.
 ► Duloxetine-induced changes in brain activation differ 
between responders and non-responders.
Design anD meThoDs
This is a single-centre, double-blind, placebo-controlled 
mechanistic study being conducted at the University of 
Nottingham (UK).
Inclusion criteria
To participate in this study, individuals must have chronic 
knee pain with radiographically defined OA changes 
(Kellgren Lawrence grade 2 or higher), be able to consent 
to participation and be aged 35 or older. They must also 
be free of major medical, neurological and psychiatric 
comorbidities known to affect neural processing of pain.
Exclusion criteria
Potential candidates meeting any of the criteria listed 
below are excluded from participation.
General:
 ► Significant medical conditions, including uncontrolled 
hypertension, insulin-dependent diabetes, dementia, 
Parkinson’s disease, epilepsy, multiple sclerosis, active 
cancer, major depressive disorder, mania, bipolar and 
schizophrenia. This is judged by a qualified physician 
based on medical records.
 ► Refusal by candidate to GP being informed.
 ► Planned total knee replacement.
MRI related:
 ► Intraocular metallic foreign bodies.
 ► Intracranial aneurysm clips.
 ► Cardiac pacemakers and defibrillators.
 ► Cochlear implants.
 ► Significant head tremor.
 ► Potential metal foreign bodies due to previous 
accidents.
 ► Breastfeeding or pregnancy, confirmed by pregnancy 
test.
 ► Unfitness for the MRI scanner, according to the 
judgement of medically qualified personnel, either 
on the research team or the patient’s clinical team 
(eg, due to back pain, claustrophobia, acute sickness, 
etc). This includes patients with signs of impaired 
temperature regulation such as an extremely high 
fever.
 ► Patients with large tattoos, specifically in the head, 
neck or shoulder region.
 ► Metallic agents embedded within the body (ie, 
Shrapnel, surgical pins).
Duloxetine related:
 ► Uncontrolled narrow-angle glaucoma.
 ► Recent usage of monoamine oxidase inhibitor or 
Mellaril (thioridazine).
 ► Taking St John’s Wort (Hypericum perforatum).
 ► On fluvoxamine, ciprofloxacin or enoxacin.
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Figure 1 Participation timeline and general characteristics of each study visit. QST, quantitative sensory testing.
 ► Taking other medicines containing duloxetine.
 ► Liver disease.
 ► Renal impairment.
 ► Currently on antidepressant treatment, including 
treatment for pain with tricyclic agents such as 
amitriptyline.
 ► Taking tramadol.
 ► Known hypersensitivity, allergy or intolerance to one 
of duloxetine's components.
 ► Unwillingness to take caution in relation to use of 
other centrally active substances such as alcohol and 
sedative drugs.
 ► Current treatment with potent inhibitors of CYP1A2 
like fluvoxamine.
 ► History of seizures or any drug lowering the seizure 
threshold.
Randomisation and blinding
Participants are randomised between duloxetine (n=54) 
and placebo (n=27). The allocation ratio is 2:1; given that 
around half of the population undergoing active treat-
ment is expected to have satisfactory pain relief, this should 
result in approximately equal numbers between groups of 
placebo intakes, responders and non-responders. A block 
randomisation, with block sizes of 9 and 2, is utilised and 
was generated by the Clinical Trials Pharmacy (CTP) at 
Nottingham University Hospitals (NHS Trust) using a pseu-
do-random algorithm at http://www. randomization. com. 
The allocation list is kept by the CTP in a password-pro-
tected file. Investigators may identify the treatment for 
each participant via request to the CTP; however, during 
treatment, this breaking the code procedure may only be 
done in the event of a medical emergency when treatment 
is dependent on knowledge of the actual drug received. In 
case the treatment code for a participant is broken or other 
actions, such as recording date or reasons for breaking the 
blind, discontinuation of trial treatment must be reported 
to the sponsor (University of Nottingham).
Participants are assigned, by the investigators, a 
unique identification number (sequentially numbered) 
and attend the university twice, for both a baseline and 
follow-up visits. Treatment consists of 6 weeks of taking 
either duloxetine capsules or placebo equivalent, followed 
by 2 weeks of dose reduction for those taking duloxetine to 
minimise drug withdrawal effects (figure 1). To minimise 
potential side effects, participants take one tablet (dulox-
etine 30 mg) daily during 2 weeks prior to switching to the 
target dose of 60 mg/day. Both researchers and partici-
pants are blinded to the treatment allocation until data 
acquisition is complete. At the end of the follow-up visit, 
individual allocation is disclosed to the participant only 
by one of the CTP staff members who are not involved 
in the any data analysis or research procedures. Data 
analysts will be blinded to treatment allocation.
Individual participation in the study is for around 
8 weeks, starting with signing informed consent and 
ending with the conclusion of the drug reduction phase.
Experimental testing
The experimental testing is primarily based on multi-
modal neuroimaging and QST, in conjunction with 
questionnaire assessment and genetics. This should 
provide a broad evaluation of the multifaceted nature 
of pain, assessing both central and peripheral mecha-
nisms, as well as psychological and cognitive traits, among 
others, which should allow pinpointing precise pheno-
typing of patients into distinct groups. Time points and 
types of data being collected are summarised in figure 2 
and details of questionnaires are given below.
Questionnaires:
 ► PainDetect (baseline)—a screening questionnaire to 
identify neuropathic components of pain.19
 ► Pain Catastrophizing Scale (PCS) (baseline)—a 13-
item scale to measure pain catastrophising, which 
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Figure 2 Details of experimental testing and randomisation 
of participants. Volume of interest for magnetic resonance 
spectroscopy is located in the midanterior cingulate 
cortex. ASL, arterial spin labelling; CPM, conditioned pain 
modulation; fMRI, functional MRI; OA, osteoarthritis; PPT, 
pressure pain thresholds; QST, quantitative sensory testing; 
Question, questionnaires; rsfMRI, resting state fMRI; T1w, T1-
weighted MRI; TS, temporal summation.
can be split into three subscales named rumination, 
magnification and helplessness.20
 ► State-Trait Anxiety Inventory (STAI) (baseline)—a 
psychological inventory assessing anxiety. It contains 
40 items and can be split into two subscales being state 
anxiety and trait anxiety.21
 ► Beck Depression Inventory II (BDI) (baseline)—a 21-
item multiple-choice self-report scale for measuring 
the severity of depression.22
 ► The intermittent and constant pain score (ICOAP) 
(baseline and follow-up)—an 11-question scale to 
characterise pain in individuals with osteoarthritis 
pain. It gives two subscales relating to intermittent 
and constant experience of pain.23
 ► The Pain Sleep Questionnaire (baseline)—a five-item 
tool to assess the impact of pain on sleep.24
 ► Brief Pain Inventory (BPI) (daily)—a nine-item 
questionnaire for measuring the severity of pain 
and the impact of this pain on daily functioning. 
The severity subscale is used to define the response 
definition (below).25
 ► Mini-Cog (baseline)—contains a three-item recall 
test and a clock drawing test to screen cognitive 
impairment.26
 ► Educational level (baseline).
 ► Questions on belief (baseline)—consist of four 
questions to assess an individual’s expectations on 
treatment and medical care.27
Participant general details:
 ► Age.
 ► Sex.
 ► Pain intensity (measured on a numeric rating scale 
ranging from 0 to 100, where 0 represents no pain at 
all and 100 stands for excruciating pain).
 ► Pain duration.
 ► Analgesia intake (last 24 hours).
 ► Caffeine intake (last 24 hours).
 ► Average daily caffeine intake.
 ► Average weekly alcohol intake.
 ► Medication.
Other:
 ► 10 mL blood samples.
 ► Analgesia diary (daily).
Response definition
Response to duloxetine is defined as a 50% reduction 
in the severity of ongoing pain from baseline to end of 
treatment, as measured by the BPI severity subscale. This 
threshold was chosen based on previous randomised 
controlled trials of duloxetine in osteoarthritis.
Primary outcomes
Treatment mechanism
1. Change in the regional response of BOLD contrast 
to pinprick nociceptive stimulation after duloxetine 
treatment (MRI2) versus baseline (MRI1) in treatment 
responder group.
2. Functional connectivity change from baseline (MRI1) 
to post duloxetine treatment (MRI2) using network 
metrics of BOLD fMRI under resting condition in 
treatment responder group.
Response prediction
3. Differences in nociceptive BOLD response and 
network function at baseline between responders and 
non-responders.
Secondary outcomes
1. Difference in the regional response of BOLD contrast 
to pinprick nociceptive stimulation after duloxetine 
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treatment (MRI2) between responder and non-
responder groups.
2. Functional connectivity differences post duloxetine 
treatment (MRI2) using network metrics of BOLD 
fMRI under resting condition between treatment 
responder and non-responder groups.
3. Correlation between baseline CPM and TS with brain 
activity and connectivity changes from baseline to post 
6 weeks of duloxetine treatment (rsfMRI and pinprick 
fMRI).
4. Group differences in brain activity (pinprick fMRI 
and rsfMRI) and structure (T1-weighted brain MRI) 
in pain processing, limbic and modulatory pathways 
changes from baseline to following 6 weeks of 
duloxetine treatment, in comparison to placebo.
5. Identification of baseline QST (CPM, TS, PPT) and 
questionnaire parameters (BDI, STAI, PCS, ICOAP) 
that predict response to duloxetine.
6. Multivariate treatment response prediction model.
other outcomes
Exploratory outcomes include, but are not limited to, 
determination of gene variations that can be linked with 
duloxetine treatment response and gamma-aminobutyric 
acid (GABA) modulation according to changes in pain 
severity. Imaging data from the baseline study may be 
pooled with other studies undertaken in the Nottingham 
Arthritis Research Pain Centre ARUKPC if the partici-
pants consent to this.
data analysis
Clinical, QST and psychometric data will be compared 
between groups and conditions using the latest versions 
of statistical and image analysis software including SPSS 
(version 21.0).
Brain imaging data will be analysed using the latest 
versions of several established toolboxes: FSL (FMRIB 
Software Library),28 PyMVPA (Multivariate Pattern Anal-
ysis),29 Statistical Parametric Mapping V.8 (London, UK), 
REST (Resting-State fMRI Data Analysis Toolkit), Brain 
Connectivity Toolbox and GRETNA (Graph Theoretical 
Network Analysis)30–32 and LCModel (Linear Combi-
nation Model) for MRS data.33 All data will undergo 
established quality control and standard recommended 
preprocessing. Preprocessing steps for functional data 
include motion correction, slice-timing correction using 
Fourier-space time-series phase-shifting, non-brain tissue 
removal, spatial coregistration to T1-weighted image and 
normalisation to the MNI anatomical standard space. 
Spatial smoothing will be carried out using an isotropic 
Gaussian kernel and a high-pass temporal filtering will be 
applied. Next, for task-related fMRI, statistical maps will 
be generated for contrasts of interest, such as to identify 
brain activity evoked by pinprick in each individual scan 
using first-level general linear model.
Z-scores will be extracted from regions of interest of pain 
processing nodes defined from meta-analysis,7 emotion 
regulatory, default mode and salience network including 
anterior cingulate cortex, anterior insula, amygdala, 
brain stem and thalamus for both task-related and resting 
functional maps. Individual functional connectivity maps 
will be also generated. These will be used on higher level 
analysis which will include, among others: (1) Paired 
t-test to evaluate treatment effects; (2) two-sample t-test 
to compare groups (responders and non-responders) at 
baseline; (3) correlation analysis to determine associa-
tions with psychometric and QST measurements.
sample size estimation
The sample size calculation was performed according to 
the guidelines stated by Lenth and colleagues.34 Estimates 
of change in functional activation were deduced from a 
duloxetine intervention study (effect size was calculated 
based on p values provided for the ACC).17 Using the Java 
applets,35 it was estimated that a one-sample, one-tailed, 
t-test would have 80% power at alpha of <0.005 (to allow 
for 10 multiple independent tests) with approximately 19 
participants per group: responders to duloxetine treat-
ment, non-responders and placebo groups.
Based on previous experience of non-usable imaging 
data due to patient and/or technical factors in 10% of 
cases, a sample size of >22 participants per group was 
necessary. A further allowance for 20% dropout gives 27 
participants in each group, resulting in a recruitment 
target of 81 participants. The study is not be powered to 
assess clinical efficacy.
recruitment
Identification of potential participants is done by 
contacting people who have taken part in previous studies 
within the ARUKPC. Recruitment through primary 
care and posters is also being used. Candidates are 
prescreened during phone call following expression of 
interest. Medical notes are verified for eligibility following 
oral consent. Suitable candidates are then booked in for 
the first visit when written informed consent is obtained 
from all individuals taking part in the study by one of the 
investigators before any interventions related to the study 
will take place. The procedure consists of the following: 
the investigator explains the details of the study and 
provides participant information sheet and drug informa-
tion leaflet, ensuring that the participant has sufficient 
time to consider participating or not. The investigator 
then answers any questions that the participant may 
have concerning study participation before signing the 
consent form.
concomitant medication
Participants are instructed not to change their regular 
pain treatment while taking part in the study. Rescue pain 
medication, taken on an ‘as needed basis’, is accepted 
during the trial period and its use is documented in a 
daily pain diary.
compliance
Compliance is assessed in the first instance by their 
attendance at all scheduled research visits. Partici-
pants who choose to discontinue are asked to inform 
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the investigators on their decision. Participants are 
contacted via telephone while undertaking the study 
medication to promote participant retention and 
completion of follow-up. During the second visit, partic-
ipants are asked whether they took the drug according 
to the protocol.
Should the participant be unwilling to reschedule their 
appointment, data collected up until that point will be 
carried forward to the analysis stages and they will be with-
drawn from the investigation. If a participant is unable to 
return for their second visit, follow-up questionnaires will 
be obtained by post.
criteria for withdrawal
Participation in this study is voluntary and participants 
are free to withdraw from the trial at any time, without 
giving any reason. However they must seek advice from 
the researchers before doing so as discontinuing dulox-
etine treatment suddenly may cause drug withdrawal 
effects. Involvement may be also discontinued by the 
investigators in case of any significant adverse effect of 
duloxetine/placebo treatment or when subjects require 
major changes to their ongoing pain management during 
the course of the study.
Adverse events and data safety monitoring
All observed or reported adverse events (AEs) are 
recorded by the investigators. No AEs are expected in 
relation to the MRI scanning. Potential AEs are antici-
pated to be only related to drug intake. All adverse events 
are recorded and monitored until resolution, stabilisa-
tion or until it has been shown that the study intervention 
is not the cause. Any serious adverse event is recorded 
and reported to the research ethics committee as part of 
the annual reports.
handling and storage of data and documents
All study staff and investigators endeavour to protect the 
rights of the trial participants to privacy and informed 
consent, and will adhere to the Data Protection Act, 1998. 
Personal data is handled confidentially. Imaging, sample 
and questionnaire data are anonymised by assigning a 
unique participant identification code, containing the 
abbreviation of the study’s name followed by a sequence 
number. The link between study identification code and 
individual's personal details is kept on the consent form 
and MR screening form.
Computer-held data are kept securely and password 
protected. All data are stored on a secure dedicated 
server. Access to data is given to the investigators and 
is restricted by user identifiers and passwords. Copies 
of the raw imaging data are also stored on CD/DVD 
in a locked room in the Radiological Sciences premises 
as back-up data. Either double data entry or checks of 
40% of data entry are to be performed to promote data 
quality.
Direct access is permitted when required to all source 
documents and other study documentation for example, 
signed consent forms, for the purpose of study moni-
toring and audit and other lawful regulatory inspection 
by the chief investigator, sponsor’s designee and inspec-
tion by relevant regulatory authorities.
The investigators have full access to the dataset without 
limiting contractual obligations.
Monitoring trial conduct
Trial conduct is subject to systems audit of the Trial Master 
File for inclusion of essential documents, permissions to 
conduct the trial, trial delegation log, curriculum vitae of 
trial staff and training received, local document control 
procedures, consent procedures and recruitment logs, 
adherence to procedures defined in the protocol (eg, 
inclusion/exclusion criteria, correct randomisation, time-
liness of visits), adverse event recording and reporting, 
drug accountability, pharmacy records and equipment 
calibration logs.
The trial coordinator or a nominated designee of the 
sponsor shall carry out a site systems audit according to 
local requirements.
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